India's Drug Controller Trapped In Crossfire Of Rival Lobbying Groups
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Deep fissures within the Indian drug industry may surface soon over regulatory reforms initiated by Drug Controller General of India Surinder Singh